POST LEONARD E 4

What Happened

• Leonard E. Post, a director of CG Oncology (CGON), exercised derivative rights to acquire 5,000 shares at $0.60 per share (total cost $3,000) and, on the same date (2026-06-22), sold 5,000 shares in an open-market transaction at $65.00 per share for total proceeds of $325,000.
• The filing also reports a disposition of 5,000 shares tied to a derivative conversion at $0.00 (reported as disposed). Footnote indicates the instrument was "Fully vested." The net activity is primarily a sale of shares following exercise.

Key Details

• Transaction date(s): June 22, 2026.
• Exercise: 5,000 shares @ $0.60 (acquired) — $3,000 total cost.
• Open-market sale: 5,000 shares @ $65.00 — $325,000 proceeds.
• Additional derivative line: 5,000 shares disposed @ $0.00 (reported as derivative conversion); footnote F2: "Fully vested."
• Sales effected pursuant to a Rule 10b5‑1 trading plan adopted March 5, 2026 (footnote F1).
• Filing date: June 23, 2026 — filed within the normal Form 4 reporting window.
• Shares owned after the transaction: not disclosed in the information provided in this summary.

Context

• The filing shows option exercise and same-day sale of the shares, which is a common pattern when insiders exercise options and immediately monetize shares; the 10b5‑1 plan indicates the sales were pre‑planned and executed under an established trading program.
• This is a routine insider sale rather than a direct purchase signal; purchases generally attract more attention as a bullish indicator.